Clinical trials: Juvenile
Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS)
Ilaris NIS in Korea
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes…
- Conditions
- Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS)
- Trial name
- REASSURE (NCT06838143)
- Testing
- Ilaris
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Myopia
Control of Myopia Using Novel Spectacle Lens Designs
Randomized, controlled, multisite, subject-and observer-masked, 3-arm parallel group clinical trial of 36-month duration to evaluate the safety and efficacy of a novel spectacle lens design in reducing the progression of juvenile…
- Trial name
- CYPRESS (NCT03623074)
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- 14 sites in United States, Canada
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Juvenile Myopia, Myopia
CYPRESS Efficacy and Safety Study Extension
This is an open-label, controlled, multisite, two-arm parallel group clinical trial of 36-month duration to evaluate the continued safety and efficacy of SightGlass Vision Diffusion Optics Technology (DOT) Spectacles in reducing…
- Trial name
- CYPRESS (NCT04947735)
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- 12 sites in United States, Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Myopia, Myopia Progression
Effect of Diffusion Optics Technology (DOT) Spectacle Lenses on Choroidal Thickness
The objective of the study is to measure the effect of Diffusion Optics Technology (DOT) spectacle lenses on the choroidal thickness and choroidal vascularity index compared to control lenses.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- ASH-2 (NCT05617794)
- Testing
- Diffusion Optics Technology (DOT) Pattern Spectacle Lens, Control Spectacle Lens
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Myopia, Myopia Progression
Spectacle Lens Visual Acuity Assessments Study
This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- CEDAR (NCT05650190)
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- 6 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Myopia, Myopia Progression
Myopia Control Spectacle Lens Cessation Study
To quantify myopic progression (cycloplegic spherical equivalent refraction - cSER) following the cessation of use of specific spectacle lenses.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- BIRCH (NCT05893979)
- Testing
- Spectacle Lenses
- Where
- 8 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Myopia, Myopia Progression
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing single vision spectacle lenses (control) versus myopia control spectacle lenses (test).
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- NCT07229352
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Myopia, Myopia Progression
Children's Viewing Behavior
The aim of this study is to investigate the area of the spectacle lens in which a subject is viewing through regardless of task being performed.
- Conditions
- Myopia, Myopia Progression, Juvenile Myopia
- Trial name
- NCT07229365
- Testing
- Novel spectacle lens design, Spectacle lenses
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Juvenile Idiopathic Arthritis
Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis
The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years in two doses (64 mg or 48 mg every 4 weeks)…
- Trial name
- NCT07517575
- Testing
- OKZ q4w
- Where
- 14 sites in Russia
- Volunteers
- 71 people
- Sponsor
- R-Pharm International, LLC
Generalized Epilepsy
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
- Trial name
- SHINE (NCT06425159)
- Testing
- BHV-7000
- Where
- 109 sites in United States, Australia and 12 more
- Volunteers
- 27 people
- Sponsor
- Biohaven Therapeutics Ltd.
Juvenile Idiopathic Arthritis
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
- Trial name
- NCT01500551
- Testing
- Tofacitinib
- Where
- 104 sites in United States, Argentina and 17 more
- Volunteers
- 302 people
- Sponsor
- Pfizer
Type 1 Diabetes Mellitus, Type 1 Diabetes
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
The purpose of this study is to establish the safety and efficacy of multiple administrations of PROCHYMAL® in participants recently diagnosed with type 1 diabetes mellitus.
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes
- Trial name
- NCT00690066
- Testing
- PROCHYMAL®
- Where
- 20 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mesoblast, Inc.
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Conditions
- Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
- Trial name
- NCT07243782
- Testing
- Secukinumab
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Idiopathic Arthritis (JIA)
HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis
Methodology: Randomized, double-blind, AB/BA cross-over study with a washout period of 12 weeks. Treatment Duration: 8 weeks per group General Objectives: To assess the efficacy and safety of multiple intravenous infusions of…
- Trial name
- NCT06623240
- Testing
- allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%
- Where
- United States
- Sponsor
- Hope Biosciences Research Foundation
Myopia, Juvenile Myopia
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy.
- Conditions
- Myopia, Juvenile Myopia, Myopia Progression
- Trial name
- EUCALYPTUS (NCT06034327)
- Testing
- Single vision, impact-resistant spectacle lenses; Test Arm, Single vision, impact-resistant spectacle lenses; Control Arm
- Where
- 14 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Juvenile Myopia, Myopia
Assessment of DOT Spectacles in Chinese Children Extension
This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing…
- Trial name
- CATHAY Ext (NCT07008001)
- Testing
- Novel spectacle lens design
- Where
- 5 sites in China
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset
Assessment of Macrophage Activation syndromE in STill's Disease in Italy
Assessment of macrophage activation syndrome in Still's disease: retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy
- Conditions
- Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset, Still's Disease, Adult-Onset
- Trial name
- AMETISTA (NCT06992505)
- Where
- 2 sites in Italy
- Volunteers
- 32 people
- Sponsor
- Swedish Orphan Biovitrum
Behçet's Disease, Juvenile Psoriatic Arthritis
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
The primary objective of this study is to evaluate the long-term safety of apremilast in subjects 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic…
- Trial name
- NCT05767047
- Testing
- Apremilast
- Where
- 7 sites in Greece, Israel and 2 more
- Volunteers
- 48 people
- Sponsor
- Amgen
Arthritis, Juvenile
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of golimumab administered intravenously (IV) to pediatric participants with…
- Trial name
- GO-VIVA (NCT02277444)
- Testing
- Golimumab, Methotrexate
- Where
- 38 sites in United States, Argentina and 7 more
- Volunteers
- 130 people
- Sponsor
- Janssen Research & Development, LLC
Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset)
R-5280 in Newly Diagnosed Patients With Type 1 Diabetes
Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
- Conditions
- Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
- Trial name
- R-5280 (NCT06057454)
- Testing
- R-5280
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Rise Therapeutics LLC